U.S. Physical Therapy, Inc. (USPH) Given Buy Rating at Cantor Fitzgerald

U.S. Physical Therapy, Inc. (NYSE:USPH)‘s stock had its “buy” rating reaffirmed by Cantor Fitzgerald in a report released on Thursday, November 2nd. They presently have a $74.00 target price on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 5.94% from the company’s previous close.

The analysts wrote, “Storm impact contained, outlook fine. Hurricanes cost an estimated $0.03 per share in 3Q17, fully diluted EPS were $0.48 (vs. our $0.52 estimate), and we are reducing our full year 2017 estimate to $2.10 (from $2.15). We are raising our 2018 estimate to $2.45 (from $2.40). Our corresponding full year adjusted EBITDA estimates (3Q17 results were about $900,000 shy of our $14.6 million estimate) are $57.7 million for 2017 (vs. prior $58.6 million) and $65.5 million (vs. prior $63.7 million ) for 2018. Commercial reimbursement rates look fine for 2018; the average reimbursement for commercial is $100 vs. Medicare’s $90.””

Several other brokerages have also recently commented on USPH. BidaskClub upgraded U.S. Physical Therapy from a “sell” rating to a “hold” rating in a report on Wednesday, October 25th. Zacks Investment Research cut U.S. Physical Therapy from a “hold” rating to a “sell” rating in a report on Saturday, October 7th. Jefferies Group LLC set a $65.00 target price on U.S. Physical Therapy and gave the stock a “hold” rating in a report on Friday, August 4th. Finally, Sidoti upgraded U.S. Physical Therapy from a “neutral” rating to a “buy” rating and raised their price target for the company from $62.00 to $74.00 in a report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $69.00.

Shares of U.S. Physical Therapy (NYSE USPH) traded up $0.65 during mid-day trading on Thursday, hitting $69.85. The stock had a trading volume of 108,450 shares, compared to its average volume of 58,322. The company has a current ratio of 2.04, a quick ratio of 2.04 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $883.20, a price-to-earnings ratio of 33.26, a PEG ratio of 2.96 and a beta of 1.07. U.S. Physical Therapy has a one year low of $56.50 and a one year high of $78.00.

U.S. Physical Therapy (NYSE:USPH) last issued its earnings results on Thursday, November 2nd. The company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.52 by ($0.04). U.S. Physical Therapy had a net margin of 5.29% and a return on equity of 13.37%. The firm had revenue of $103.03 million during the quarter, compared to analyst estimates of $102.69 million. equities analysts expect that U.S. Physical Therapy will post 2.07 EPS for the current fiscal year.

WARNING: “U.S. Physical Therapy, Inc. (USPH) Given Buy Rating at Cantor Fitzgerald” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://baseballnewssource.com/markets/cantor-fitzgerald-reiterates-buy-rating-for-u-s-physical-therapy-inc-usph/1751087.html.

In related news, CFO Lawrance W. Mcafee sold 800 shares of U.S. Physical Therapy stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $69.21, for a total value of $55,368.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Christopher J. Reading sold 15,000 shares of U.S. Physical Therapy stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $66.52, for a total value of $997,800.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 26,602 shares of company stock worth $1,740,976. 3.10% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of USPH. BlackRock Inc. grew its stake in U.S. Physical Therapy by 166,319.0% in the first quarter. BlackRock Inc. now owns 1,554,353 shares of the company’s stock valued at $101,501,000 after purchasing an additional 1,553,419 shares in the last quarter. Aberdeen Asset Management PLC UK boosted its stake in shares of U.S. Physical Therapy by 13.4% during the 2nd quarter. Aberdeen Asset Management PLC UK now owns 705,007 shares of the company’s stock worth $42,582,000 after acquiring an additional 83,253 shares during the period. Renaissance Technologies LLC boosted its stake in shares of U.S. Physical Therapy by 10.4% during the 2nd quarter. Renaissance Technologies LLC now owns 668,074 shares of the company’s stock worth $40,352,000 after acquiring an additional 63,074 shares during the period. Vanguard Group Inc. boosted its stake in shares of U.S. Physical Therapy by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 641,533 shares of the company’s stock worth $41,892,000 after acquiring an additional 39,290 shares during the period. Finally, Bridge City Capital LLC bought a new position in shares of U.S. Physical Therapy during the 2nd quarter worth approximately $1,760,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

About U.S. Physical Therapy

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.

Receive News & Ratings for U.S. Physical Therapy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.